Young Kwang Chae

Young Kwang Chae is a Professor of Medicine specializing in Hematology and Oncology at the Feinberg School of Medicine, Northwestern University. He is affiliated with the Robert H. Lurie Comprehensive Cancer Center and the Northwestern University Clinical and Translational Sciences Institute (NUCATS).

Education:

• MD: Seoul National University, Korea (2002)
• MBA: Johns Hopkins University (2007)
• MPH: Johns Hopkins University (2007)
• Residency: Albert Einstein Medical Center, Internal Medicine (2011)
• Fellowship: University of Texas/MD Anderson Cancer Center, Hematology-Oncology (2014)

Research Interests:

Dr. Chae is a leading researcher in personalized cancer therapy and precision medicine. His work focuses on developing novel cancer treatments through early phase clinical trials and first-in-human studies. He has particular expertise in novel combination cancer therapies, targeted therapy, and immunotherapy approaches. His research also encompasses biomarker studies, novel drug development, and innovative drug delivery systems. Dr. Chae is known for his work on adaptive clinical trial designs that optimize patient outcomes based on molecular and immunological profiles of tumors. His investigations into cell signaling pathways and immune checkpoint pathways have contributed significantly to understanding cancer biology and treatment resistance mechanisms.

Publication Trends:

Dr. Chae's recent publications demonstrate a strong focus on immunotherapy applications across various cancer types, particularly in rare tumors and non-small cell lung cancer. His work integrates advanced technologies like artificial intelligence for digital pathology analysis and radiomics for predicting treatment response. A significant portion of his research examines combination therapies targeting multiple immune pathways simultaneously. Dr. Chae also investigates the intersection of transplantation medicine and oncology, exploring relationships between graft rejection and post-transplant malignancies.

Scientific Awards:

• ASCO/AACR Translational Cancer Research Award, Conquer Cancer Foundation (2013)
• The AACR-GlaxoSmithKline Outstanding Clinical Scholar Award, American Association for Cancer Research (AACR) (2013)
• The Allison and Brian Grove Endowed Fellowship Award for Breast Medical Oncology, The University of Texas MD Anderson Cancer Center (2013)

Advising and Grants:

Dr. Chae leads multiple clinical trials focusing on advanced cancer therapies. His current research portfolio includes a master protocol evaluating biomarker-driven therapies in non-small cell lung cancer (Lung-MAP Screening Study), a randomized phase II/III trial of immunotherapy with or without stereotactic body radiation therapy for PD-L1-negative advanced non-small cell lung cancer, and multimodality therapy with immunotherapy for sarcomatoid mesothelioma. He also oversees the TEMPUS GEMINI NSCLC Surveillance Study, a longitudinal multi-omic biomarker profiling study. His industry relationships include collaborations with AstraZeneca, Caris Life Sciences, Guardant Health, Janssen Pharmaceuticals, Novocure, and Regeneron Pharmaceuticals for consulting and advisory activities.

Laboratories and Research Teams:

Dr. Chae is affiliated with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, where he leads a research team focused on translational oncology. His work bridges basic science discoveries with clinical applications through the Northwestern University Clinical and Translational Sciences Institute (NUCATS). His research group collaborates extensively with bioinformaticians, radiologists, pathologists, and other specialists to develop integrated approaches to cancer treatment.